Is Repligen Corp. overvalued or undervalued?

As of 12 November 2024, Repligen Corp. has moved from an expensive to a risky valuation grade. The company appears to be overvalued, given its high P/E ratio of 210, significantly above its peer average of 181.22, and an EV to EBITDA ratio of 56.65, which also exceeds the industry benchmarks. Additionally, the Price to Book Value stands at 3.63, indicating a premium over its book value compared to peers like Neurocrine Biosciences, which has a P/E of 37.08.
In terms of performance, Repligen Corp. has underperformed relative to the S&P 500, with a year-to-date return of -13.59% compared to the index's 12.22%. Over the past three years, the stock has declined by 43.80%, while the S&P 500 has gained 70.41%, reinforcing the notion that the stock is currently overvalued.